I. Introduction   Histamine was first discovered in the last century. It is the main medium for many biological reactions including allergic reactions. Some of these biological reactions are involved in the pathophysiological processes of common skin diseases. In theory, there are three ways to block the biological effects… Continue Reading Antihistamines for itch treatment

  Immunotherapy is considered to be the fourth pillar of cancer treatment (in parallel with surgery, radiotherapy, and chemotherapy), by enhancing the ability of the immune system to target and kill tumor cells, including: 1) Blocking antibodies to the inhibitory immune checkpoint pathway 2) Cell therapy based on dendritic cells… Continue Reading Nature: The next step in cancer immunotherapy is joint therapy. Eradication of cancer is not the ultimate goal.

  Lupus erythematosus (LE) is a typical autoimmune connective tissue disease and a disease-causing disease. One end of the spectrum is cutaneous lupus erythematosus (CLE), the lesion is mainly confined to the skin; the other end is systemic lupus erythematosus (SLE), in addition to skin damage, the lesion involves multiple… Continue Reading Pathogenesis of skin-type lupus erythematosus and analysis of 9 new treatments

  From the discovery of tubulin to the approval of vinblastine for anticancer treatment, it has been more than half a century. Microtubules play an extremely important role in cell division, and disruption of the formation of mitotic spindles affects all dividing cells. For cancer cells that proliferate faster than… Continue Reading The development of microtubule inhibitors – the big story of small molecules

  On July 31, Merck announced that the FDA approved Keytruda monotherapy for patients with recurrent locally advanced or metastatic esophageal squamous cell carcinoma who had previously received at least one line of systemic PD-L1 expression (CPS ≥ 10). This approval is based primarily on data from two studies. One… Continue Reading Keytruda new indications approved, the first esophageal cancer PD-1 therapy

  I. Penicillins Penicillin can be divided into: narrow-spectrum penicillin, penicillin-resistant penicillin, broad-spectrum penicillin against Enterobacter, and broad-spectrum penicillin against Pseudomonas aeruginosa. Narrow-spectrum penicillin: penicillin G, procaine penicillin, benzathine penicillin, penicillin V, etc., mainly acting on penicillin of Gram-positive bacteria Penicillin-resistant penicillin: oxacillin, cloxacillin, flucloxacillin, etc., antibacterial spectrum similar to… Continue Reading Antibacterial spectrum of antibacterial drugs

  Lupus erythematosus is an autoimmune inflammatory connective tissue disease. From the perspective of pathogenesis, the mainstream view is that genetic factors, environmental factors, estrogen levels and other factors interact to cause excessive proliferation of B cells in patients, resulting in a large number of autoantibodies. The antibody binds to… Continue Reading The first new drug for lupus erythematosus, Belimumab was approved for listing in China

  Vitamins and trace elements play an important role in the development of type 2 diabetes and its complications. Among the many vitamins and trace elements, some are beneficial to diabetic patients, some are harmful to diabetic patients, and you can’t make up for it!   I. Which vitamins are… Continue Reading Which vitamins and trace elements are beneficial for patients with type 2 diabetes?

  The prototype of the best-selling book “The Billion-Dollar Molecule” in the pharmaceutical industry is Vertex. The company, which was founded in 1989, started with $10 million in funds and can be said to be a dark horse enterprise in the pharmaceutical industry. Vertex has created three drugs with annual… Continue Reading “The Billion-Dollar Molecule” prototype Vertex’s “Next City”